{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.6","value":"71.1"},{"groupId":"OG001","spread":"15.8","value":"71.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"300"},{"groupId":"OG001","value":"148"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.86","value":"1.65"},{"groupId":"OG001","spread":"10.2","value":"1.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.2","value":"1.24"},{"groupId":"OG001","spread":"13.0","value":"3.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"127"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.9","value":"1.82"},{"groupId":"OG001","spread":"16.9","value":"4.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.1","value":"0.69"},{"groupId":"OG001","spread":"16.4","value":"6.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.4","value":"1.55"},{"groupId":"OG001","spread":"13.1","value":"5.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"48"}],"units":"Participants"}],"title":"Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.5","value":"3.01"},{"groupId":"OG001","spread":"12.9","value":"5.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.5","value":"2.7"},{"groupId":"OG001","spread":"10.9","value":"3.98"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"Cycle 7 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.1","value":"4.12"},{"groupId":"OG001","spread":"14.8","value":"7.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.2","value":"4.19"},{"groupId":"OG001","spread":"16.7","value":"7.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"Cycle 9 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.1","value":"5.14"},{"groupId":"OG001","spread":"18.7","value":"6.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Cycle 10 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.7","value":"2.58"},{"groupId":"OG001","spread":"15.4","value":"0.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Cycle 11 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.0","value":"2.11"},{"groupId":"OG001","spread":"13.1","value":"4.63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.4","value":"6.29"},{"groupId":"OG001","spread":"3.27","value":"10.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 13 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.4","value":"3.64"},{"groupId":"OG001","spread":"4.55","value":"14.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 14 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.9","value":"8.40"},{"groupId":"OG001","spread":"3.46","value":"12.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 15 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.99","value":"5.83"},{"groupId":"OG001","spread":"0.0","value":"15.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.1","value":"15.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Cycle 17 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.1","value":"5.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Cycle 18 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.3","value":"-4.77"},{"groupId":"OG001","spread":"16.7","value":"-3.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"49"}],"units":"Participants"}],"title":"30 days post-study"}],"denoms":[{"counts":[{"groupId":"OG000","value":"300"},{"groupId":"OG001","value":"148"}],"units":"Participants"}],"description":"Patients indicate their present health state through completion of the VAS. Possible scores range from 0 (worst imaginable health state) to 100 (best imaginable health state).","dispersionType":"Standard Deviation","groups":[{"description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care","id":"OG000","title":"Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed"},{"description":"pemetrexed + cisplatin followed by placebo plus best supportive care","id":"OG001","title":"Pemetrexed + Cisplatin Followed by Placebo"}],"paramType":"MEAN","populationDescription":"Participants who were randomized and completed the EQ-5D at baseline and at least once post-baseline. For Cycle 17 and 18, there is no data available for the pemetrexed + cisplatin followed by placebo arm. No participants completed so zero participants were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline randomization through 30-day post-discontinuation visit (up to 19.3 months)","title":"Change From Baseline in EuroQol Instrument (EQ-5D) Visual Analog Scale (VAS)","type":"SECONDARY","unitOfMeasure":"units on a scale"}